Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- fulltext
Final published version, 1.64 MB, PDF document
Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a T-score of > −2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in women with osteoporosis, ≥55 years of age, after the following treatment sequences: 1 year romosozumab followed by 2 years denosumab (FRAME and FRAME extension trials), 1 year romosozumab followed by 2 years alendronate, or alendronate-only for 3 years (ARCH trial). Probabilities of attaining the BMD target within 1 year of treatment were also determined. At both skeletal sites, in women with a baseline Tscore ≥ −2.7, there was >50% probability of achieving the BMD target with any 3-year regimen. The probability of achieving the target BMD in those with a baseline TH Tscore equal to −3.0 was 61% with romosozumab/denosumab, 38% with romosozumab/alendronate, and 9% with alendronate. In those with a baseline LS Tscore equal to −3.0, the probability of achieving a T-score > −2.5 was 93% with romosozumab/denosumab, 81% with romosozumab/alendronate, and 55% with alendronate. With 1 year of treatment, in patients with a baseline TH T-score equal to −2.7, the probability of reaching the target Tscore with romosozumab was 71% to 78% and 38% with alendronate. For patients with an initial LS T-score equal to −3.0, the probability of achieving the target T-score over 1 year was 85% to 86% with romosozumab and 25% for alendronate. Our findings suggest baseline BMD and the probability of achieving BMD T-score goals are factors to consider when selecting initial treatment for patients with osteoporosis. As baseline T-score falls below −2.7 (TH) and −3.0 (LS), alendronate has <50% likelihood of achieving a BMD goal above osteoporosis range, whereas these probabilities remain relatively high for regimens beginning with romosozumab.
| Original language | English |
|---|---|
| Article number | e10546 |
| Journal | JBMR Plus |
| Volume | 5 |
| Issue number | 11 |
| Number of pages | 9 |
| ISSN | 2473-4039 |
| DOIs | |
| Publication status | Published - 2021 |
Bibliographical note
Funding Information:
CD, ZW, ZY: Employees of Amgen. CL: Employee and stockholder of UCB Pharma. EH: Consulting/speaker fees from Amgen, UCB Pharma, Lilly, Ipsen, Theramex, AgNovos, and Alexion. EL: Consulting/speaker fees from Amgen, Lilly, Theramex, and UCB Pharma. FC: Received institutional grants and research support from Amgen; has served as a consultant for Amgen and Radius Health; and has served on the speakers' bureaus for Amgen and Radius Health. FB: Consulting/speaker fees from Amgen, UCB Pharma, Lilly, Abiogen, Astellas, Janssen, and Chiesi Farmaceutici. J‐EBJ: Advisory boards: Amgen, Eli Lilly, UCB Pharma, and Gedeon Richter; lectures: Amgen, Eli Lilly, UCB Pharma, Gilead, and Otsuka. PP: Consulting/speaker fees from Amgen, UCB Pharma, Lilly, Kyowa and Kirin. SF: Received research and/or consulting grants from Amgen, UCB Pharma, Radius, Agnovos, Alexion, and Gedeon Richter. SRC: Consultant and honoraria for speaking from Amgen.
Funding Information:
The authors thank the patients, the investigators, and their teams who took part in this study. The authors also acknowledge Jen Timoshanko, UCB Pharma, Slough, UK, for publication coordination and Hannah Brechka, PhD, from Costello Medical, UK, for medical writing and editorial assistance based on the authors' input and direction in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This study was sponsored by UCB Pharma and Amgen Inc. Authors? roles: Substantial contributions to study conception and design: FC, CL, ZY, ZW, SF, PP, FB, EL, EH, and SRC. Substantial contributions to acquisition of data: FC, CL, ZY, ZW, SF, JEBJ, PP, FB, EL, EH, and SRC. Substantial contributions to analysis and interpretation of data: FC, CL, CD, ZY, ZW, SF, PP, FB, EL, EH, and SRC. Drafting the article or revising it critically for important intellectual content: FC, CL, CD, ZY, ZW, SF, JEBJ, PP, FB, EL, EH, and SRC. Final approval of the version of the article to be published: FC, CL, CD, ZY, ZW, SF, JEBJ, PP, FB, EL, EH, and SRC.
Publisher Copyright:
© 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- ANABOLICS, ANTIRESORPTIVES, CLINICAL TRIALS, DXA, OSTEOPOROSIS
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 301696689